European heart journal · 2026
Oral magnesium and outcomes in US veterans with heart failure.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yin Ying, Costello Rebecca B, Fonarow Gregg C, Heidenreich Paul A, Morgan Charity J, Faselis Charles, Cheng Yan, Zullo Andrew R, Liu Simin, Lam Phillip H, Rosanoff Andrea, Vargas Jose D, Gottlieb Stephen S, Deedwania Prakash, Moore Hans J, Shao Yijun, Sheriff Helen M, Wu Wen-Chih, Zeng-Treitler Qing, Ahmed Ali
Аннотация
BACKGROUND AND AIMS: Magnesium deficiency is associated with poor outcomes in patients with heart failure (HF), but less is known about the impact of oral magnesium therapy. This study aimed to examine the association of oral magnesium with outcomes in patients with HF and whether it depends on baseline serum magnesium.
METHODS: Of 54 696 Veterans with HF (2001-2023) and hypomagnesemia (serum magnesium <1.7 mg/dL), 10 695 were initiated on oral magnesium (median dose, 420 mg/day). A propensity score-matched cohort of 21 098 patients (treated, n = 10 549) balanced on 71 baseline characteristics was assembled while remaining outcome-blinded. This process was repeated to assemble a matched cohort of 11 634 patients (treated, n = 5817) with normomagnesemia (serum magnesium, 1.7-2.3 mg/dL). Hazard ratios (HR) (95% confidence intervals [CIs]) for one-year outcomes associated with oral magnesium were estimated.
RESULTS: In the hypomagnesemia cohort, HF hospitalization or death occurred in 21.7% of patients not receiving and 20.1% receiving oral magnesium (HR: 0.91; 95% CI: 0.86-0.97). Respective HRs (95% CIs) in subgroups with serum magnesium 1.6 (n = 5929), 1.3-1.5 (n = 11 293) and <1.3 (n = 3876) mg/dL were 0.99 (0.88-1.12), 0.91 (0.84-0.98; interaction P = .20), and 0.81 (0.71-0.93; interaction P = .03). Respective rates in the normomagnesemia cohort were 17.8% and 19.5% (HR: 1.11; 95% CI: 1.02-1.21). Spline regression analysis revealed that HRs were lower at serum magnesium <1.5 mg/dL, higher at >1.8 mg/dL, and not significant at 1.5-1.8 mg/dL.
CONCLUSIONS: Oral magnesium therapy was associated with a lower risk of HF hospitalization or death in patients with HF and hypomagnesemia. Future clinical trials need to confirm these findings.
METHODS: Of 54 696 Veterans with HF (2001-2023) and hypomagnesemia (serum magnesium <1.7 mg/dL), 10 695 were initiated on oral magnesium (median dose, 420 mg/day). A propensity score-matched cohort of 21 098 patients (treated, n = 10 549) balanced on 71 baseline characteristics was assembled while remaining outcome-blinded. This process was repeated to assemble a matched cohort of 11 634 patients (treated, n = 5817) with normomagnesemia (serum magnesium, 1.7-2.3 mg/dL). Hazard ratios (HR) (95% confidence intervals [CIs]) for one-year outcomes associated with oral magnesium were estimated.
RESULTS: In the hypomagnesemia cohort, HF hospitalization or death occurred in 21.7% of patients not receiving and 20.1% receiving oral magnesium (HR: 0.91; 95% CI: 0.86-0.97). Respective HRs (95% CIs) in subgroups with serum magnesium 1.6 (n = 5929), 1.3-1.5 (n = 11 293) and <1.3 (n = 3876) mg/dL were 0.99 (0.88-1.12), 0.91 (0.84-0.98; interaction P = .20), and 0.81 (0.71-0.93; interaction P = .03). Respective rates in the normomagnesemia cohort were 17.8% and 19.5% (HR: 1.11; 95% CI: 1.02-1.21). Spline regression analysis revealed that HRs were lower at serum magnesium <1.5 mg/dL, higher at >1.8 mg/dL, and not significant at 1.5-1.8 mg/dL.
CONCLUSIONS: Oral magnesium therapy was associated with a lower risk of HF hospitalization or death in patients with HF and hypomagnesemia. Future clinical trials need to confirm these findings.